Philip Theodore, Senior Vice President, ptheodore@aezsinc.comCopyright CNW Group 2015
Aeterna Zentaris Confirms No Corporate Developments
View original source (CNW)COSCIENS Biopharma Inc. on 6ix
Earlier from COSCIENS Biopharma
- Aeterna Zentaris Announces Exercise of Last Series B Warrants Covered by November 1, 2015 Agreement
- Aeterna Zentaris Announces First Patient Enrolled for Confirmatory Phase 3 Trial of Macrilen(TM) for the evaluation of AGHD
- Aeterna Zentaris Announces Details and Implementation of Share Consolidation to Regain NASDAQ Compliance
- Aeterna Zentaris Announces Shareholder Approval of Share Consolidation
- Aeterna Zentaris Announces Exercise of Series B Warrants
Later from COSCIENS Biopharma
- Aeterna Zentaris Affirms Fundamental Strength of Business
- Research Reports Initiated on Healthcare Stocks Resverlogix, Immunovaccine, IntelliPharmaCeutics International, and Aeterna Zentaris
- CORRECTION FROM SOURCE: IIROC Trade Resumption - Aeterna Zentaris Inc.
- JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th
- JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th
Follow COSCIENS Biopharma into a list and get an email when it puts out news.
Follow COSCIENS Biopharma